According to the Market Statsville Group (MSG), the global terlipressin market size is expected to grow from USD 2.5 million in 2022 to USD 4.5 million by 2033, growing at a CAGR of 5.4% from 2023 to 2033. The increasing occurrence of liver and kidney decreases with impaired kidney function that is hepatorenal syndrome is stimulating the growth of the Terlipressin Market. Moreover, Due to the China-US trade war and the economic volatility and uncertainty worldwide, the industry is likely to witness a slowdown in the market over the forecasting period. The increasing low blood presser among the adults and old age population has created a lot of opportunities in this market for the player to capture the market over the forecast period of time.

Definition of the Global Terlipressin Market

Terlipressin is a synthetic counterpart of vasopressin, an endogenous neurohormone with vasoconstrictive properties. It is a layperson prodrug, also known as lysine vasopressin. Terlipressin has a longer half-life and greater specificity for the V1 receptor than natural vasopressin. Terlipressin has been studied as a powerful vasopressor in several shock states and situations with decreased vasomotor tone. It was also investigated in the treatment of hepatorenal syndrome (HRS) and variceal bleeding.

Terlipressin, also known as Terlivaz, is an analogue of vasopressin that is used as a vasoactive medication in the treatment of low blood pressure. It has been shown to be useful when norepinephrine is ineffective.

COVID-19 Impact on the Global Terlipressin Market

The COVID-19 began in Wuhan (China) in December 2019 and has since expanded rapidly around the world. In terms of confirmed cases and reported deaths, the United States, India, Brazil, Russia, France, the United Kingdom, Turkey, Italy, and Spain are among the worst impacted nations. Due to lockdowns, travel bans, and commercial shutdowns, the COVID-19 has had an impact on economies and businesses in a number of nations. The COVID-19 pandemic has had a significant influence on the healthcare business, posing new obstacles for healthcare providers. The pandemic has also had an influence on the terlipressin market, which is predicted to increase at a slower rate as a result of the epidemic's economic impact.

Global Terlipressin Market Dynamics

Drivers: Increasing number of blood pressure patient around the world

The increase blood pressure and unhealthy diet plan has boosted the market growth over the forecasting period. According to, blood pressure UK association, there are over 4.2 million people were screened in almost 100 countries and almost 1 million people identified with untreated or inadequately treated hypertension. The largest rises in high blood pressure has been seen in South Asia, including in Bangladesh and Nepal, and Sub-Saharan Africa, including in Ethiopia and Malawi. Around a third of women have high blood pressure in most countries in West Africa, including Niger, Chad, and Mali. In addition surge in old age people in all around the world has also boosted the market over the forecast period. According to WHO, the number of adults aged 30–79 years with hypertension has increased from 650 million to 1.28 billion in the last thirty years.

Restraints: Risk of side effects

Terlipressin is used to treat cirrhotic individuals with bleeding oesophageal varices and hepatorenal syndrome. In some cases, adverse effects are mild, but there is a considerable risk of side effects. However, potentially dangerous adverse effects such as skin necrosis of the limbs, scrotum, trunk, and abdominal skin are uncommon. The most common adverse effects are pallor, headache, abdominal pain, bradycardia, and hypertension. The rate of adverse events was 50.0% with terlipressin treatment. The majority of terlipressin-related adverse effects were mild or moderate, and they resolved on their own without any intervention. This has hindered the market growth over the forecasting period.

Opportunities: Increasing Patient of liver and kidney hepatorenal syndrome

Terlipressin Market growth is influenced by the increasing incidence of liver and kidney disease associated with impaired kidney function, also known as hepatorenal syndrome. Terlipressin, a vasoconstrictor, is used to treat type 1 hepatorenal syndrome (HRS-1) in various regions of the world and is included in clinical practise recommendations in Europe. Due to unhealth lifestyle and hypertension among the adults and old aged people can lead to kidney failure that occurs in a person with cirrhosis of the liver. It is a serious complication that can lead to death. To treat this doctors prefer Terlipressin drug and this has created a lots of opportunities for this in the market over the forecast period.

Scope of the Global Terlipressin Market

The study categorizes the terlipressin market based on type, and application area at the regional and global levels.

By Type Outlook (Sales, USD Million, 2019-2033)

• ≥98%
• <98%

By Application Outlook (Sales, USD Million, 2019-2033)

• Injection
• Other

By Region Outlook (Sales, USD Million, 2019-2033)

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Italy
  • France
  • UK
  • Spain
  • Poland
  • Russia
  • The Netherlands
  • Norway
  • Czech Republic
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Malaysia
  • Thailand
  • Singapore
  • Australia & New Zealand
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Rest of South America
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Northern Africa
  • Rest of MEA

Injection segment accounts for the largest market share by application

Based on the type, the market is divided into injections and others. The injection segment is expected to dominate the market share in 2022 in the global terlipressin market. Throughout the last decade, public health data show a rise in the number of persons who inject drugs (PWID) in the United States. Terlipressin is administered through vein injection under the guidance of a doctor. This causes the patient to feel dizzy or lightheaded and reduces the chances of passing out. Due to the rapid onset of the action compared to that of the oral and the subcutaneous routes this segment had registered the largest market share over the forecasting period.

Asia Pacific is expected to witness the largest market share by Region

Based on the regions, the global terlipressin market has been segmented across Europe, North America, the Middle East & Africa, Asia-Pacific, and South America. Asia Pacific is projected to account for the highest market share in 2022. Growing old age population and two most populated counties India and China in this region has boost the market over the forecasting period. According to Census Bureau, among Asian subregions there are 33.7% of the population of Eastern Asia is expected to be 65 or older by 2060. Southern Asia (18.6%) and Western Asia (17.9%), on the other hand, are predicted to have the lowest shares of elderly persons in their respective total populations.

Competitive Landscape: Global Terlipressin Market

The terlipressin market is a significant competitor, and extremely cutthroat in the sector are using strategies including product launches, partnerships, acquisitions, agreements, and growth to enhance their market positions. Most sector businesses focus on increasing their operations worldwide and cultivating long-lasting partnerships.

Major key players in the global terlipressin market are:

• EVER Pharma
• Hybio Pharmaceutical
• Sun Pharmaceutical Industries Ltd
• Shanghai Soho-Yiming Pharmaceuticals
• Xi ‘an langene biological technology
• SGPharma
• Company 7
• Company 8
• Company 9
• Company 10
• Company 11

Key Issues Addressed

• What is the market size by various segmentation of the terlipressin by region and its respective countries?
• What are the customer buying behavior, key takeaways, and Porter's 5 forces of the terlipressin market?
• What are the key opportunities and trends for manufacturers involved in the terlipressin supply chain?
• What are the fundamental dynamics (drivers, restraints, opportunities, and challenges) of the market?
• What and how regulations, schemes, patents, and policies are impacting the growth of the market?
• What are the upcoming technological solutions influencing market trends? How will existing companies adapt to the new change in technology?
• The market player positioning, top winning strategies by years, company product developments, and launches will be?
• How has COVID-19 impacted the demand and sales of terlipressin in the global market? Also, the expected BPS drop or rise count of the market and market predicted recovery period.
• Detailed analysis of the competitors and their latest launch, and what are the prominent startups introduced in the target market? Also, detailed company profiling of 25+ leading and prominent companies in the market.